Candidiasis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 105 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Candidiasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2014', provides an overview of the Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Candidiasis Overview 10
Therapeutics Development 11
Pipeline Products for Candidiasis - Overview 11
Pipeline Products for Candidiasis - Comparative Analysis 12
Candidiasis - Therapeutics under Development by Companies 13
Candidiasis - Therapeutics under Investigation by Universities/Institutes 15
Candidiasis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Candidiasis - Products under Development by Companies 19
Candidiasis - Products under Investigation by Universities/Institutes 20
Candidiasis - Companies Involved in Therapeutics Development 21
Sequella, Inc. 21
Merck & Co., Inc. 22
Novartis AG 23
Eisai Co., Ltd. 24
iCo Therapeutics Inc. 25
Basilea Pharmaceutica AG 26
Pacgen Life Science Corporation 27
Novabiotics Ltd 28
NovaDigm Therapeutics, Inc. 29
Cellceutix Corporation 30
Aureogen Biosciences, Inc. 31
Sealife PHARMA GMBH 32
Panacela Labs, Inc. 33
Biomar Microbial Technologies 34
Candidiasis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
posaconazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
isavuconazonium sulfate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PAC-113 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NDV-3 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SQ-109 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PMX-30016 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
amphotericin b - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NP-339 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
E-1210 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SLP-0904 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SLP-0901 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Xenomycin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AUGC-15 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecule for Candidiasis - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule for Cryptococcosis and Candidiasis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PMX-1502 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PMX-519 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
candida vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PMX-1408 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
E-1211 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NVN-4428 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drugs for Fungal Infections - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules for Candidiasis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule for Candidiasis and Cryptococcosis - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PMX-1570 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PMX-1576 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PMX-1591 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PMX-1625 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Candidiasis - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Candidiasis - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Fungal Infections - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
AUGC-10 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Candidiasis - Recent Pipeline Updates 82
Candidiasis - Dormant Projects 92
Candidiasis - Discontinued Products 93
Candidiasis - Product Development Milestones 94
Featured News & Press Releases 94
Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis 94
Mar 17, 2014: Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL Injection for Intravenous Use, a New Captisol-enabled Formulation 94
Mar 14, 2014: FDA Approves Merck's NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use 95
Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections 96
Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections 96
Nov 18, 2013: Merck's New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review 97
Sep 13, 2013: Basilea reports presentation of posters at ICAAC on investigational anti-infective isavuconazole 99
Jul 17, 2013: Basilea provides update on isavuconazole phase 3 program 101
Jun 24, 2013: FDA Approves Pediatric Indication For Astellas's Mycamine For Injection 101
Apr 29, 2013: Basilea Pharma Presents Data On Anti-fungal Drug Candidate Isavuconazole At ECCMID 2013 102
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables
Number of Products under Development for Candidiasis, H2 2014 11
Number of Products under Development for Candidiasis - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Candidiasis - Pipeline by Sequella, Inc., H2 2014 21
Candidiasis - Pipeline by Merck & Co., Inc., H2 2014 22
Candidiasis - Pipeline by Novartis AG, H2 2014 23
Candidiasis - Pipeline by Eisai Co., Ltd., H2 2014 24
Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2014 25
Candidiasis - Pipeline by Basilea Pharmaceutica AG, H2 2014 26
Candidiasis - Pipeline by Pacgen Life Science Corporation, H2 2014 27
Candidiasis - Pipeline by Novabiotics Ltd, H2 2014 28
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2014 29
Candidiasis - Pipeline by Cellceutix Corporation, H2 2014 30
Candidiasis - Pipeline by Aureogen Biosciences, Inc., H2 2014 31
Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2014 32
Candidiasis - Pipeline by Panacela Labs, Inc., H2 2014 33
Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Candidiasis Therapeutics - Recent Pipeline Updates, H2 2014 82
Candidiasis - Dormant Projects, H2 2014 92
Candidiasis - Discontinued Products, H2 2014 93